Oxidative stress in children receiving valproic acid

Journal of Pediatrics

Volumn 149, Issue 5, 2006, Pages 692-696

  Michoulas, Aspasia ^a   Tong, Vincent ^a   Teng, Xiao Wei ^a   Chang, Thomas K H ^a   Abbott, Frank S ^a   Farrell, Kevin ^a  

^a Faculty of Pharmaceutical Sciences   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBAMAZEPINE; CLOBAZAM; ISOPROSTANE DERIVATIVE; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; SIDE EFFECT; SMOKING; URINALYSIS;

ADOLESCENT; AGE FACTORS; ANTICONVULSANTS; BENZODIAZEPINES; BIOLOGICAL MARKERS; CANADA; CARBAMAZEPINE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CREATININE; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; TOBACCO SMOKE POLLUTION; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33750620015     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.08.015     Document Type: Article

References (45)

1. Zimmerman H.J., and Ishak K.G. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2 (1982) 591-597
2. Bryant A.E., and Dreifuss F.E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46 (1996) 465-469
3. Dreifuss F.E., Santilli N., Langer D.H., Sweeney K.P., Moline K.A., and Menander K.B. Valproic acid hepatic fatalities: a retrospective review. Neurology 37 (1987) 379-385
4. Dreifuss F.E., Langer D.H., Moline K.A., and Maxwell J.E. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 39 (1989) 201-207
5. Pippenger C.E., Xianzhong M., Rothner A.D., Cruse R.P., Erenberg G., and Solano R. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions: probable mechanisms for valproate-induced acute pancreatitis and hepatotoxicity. In: Levy R.H., and Penry J.K. (Eds). Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity (1991), Raven press, New York 75-88
6. Wilder B.J., and Hurd R.W. Free radical scavenger deficiency and valproic acid. In: Levy R.H., and Penry J.K. (Eds). Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity (1991), Raven press, New York 89-95
7. Buchi K.N., Gray P.D., Rollins D.E., and Tolman F.G. Protection against sodium valproate injury in isolated hepatocytes by alpha-tocopherol and N, N'-diphenyl-p-phenylenediamine. J Clin Pharmacol 24 (1984) 148-154
8. Yuksel A., Cengiz M., Seven M., and Ulutin T. Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two year prospective studies. J Child Neurol 16 (2001) 603-606
9. Cotariu D., Evans S., Zaidman J.L., and Marcus O. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem Pharmacol 40 (1990) 589-593
10. Tabatabaei A.R., Thies R.L., and Abbott F.S. Assessing the mechanism of metabolism dependent valproic acid-induced in vitro cytotoxicity. Chem Res Toxicol 12 (1999) 323-330
11. Graf W.D., Oleinik O.E., Glauser T.A., Maertens P., Eder D.N., and Pippenger C.E. Altered antioxidant enzyme activities in children with serious adverse experience related to valproic acid therapy. Neuropediatrics 29 (1998) 195-201
12. Hurd R.W., Van Rinsvelt H.A., Wilder B.J., Karas B., Maenhaut W., and De Reu L. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. Neurology 34 (1984) 1393-1395
13. Farrell K., and Abbott F.S. Role of N-acetylcysteine in the treatment of valproate hepatotoxicity. In: Levy R.H., and Penry J.K. (Eds). Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity (1991), Raven Press, New York 149-153
14. 2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical catalyzed mechanism. Proc Natl Acad Sci USA 87 (1990) 9383-9387
15. Roberts L.J., and Morrow J. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Rad Biol Med 28 (2000) 505-513
16. Morrow J.D., Chen Y., Brame C.J., Yang J., Sanchez S.C., Xu J., et al. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metabolism Reviews 31 (1999) 117-139
17. Practico D. F2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147 (1999) 1-10
18. 2-Isoprostane excretion rate and diurnal variation in human urine. Prostaglandins, Leukotrienes and Essential Fatty Acids 61 (1999) 203-205
19. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters 368 (1995) 225-229
20. Baraldi E., Ghiro L., Piovan V., Carraro S., Ciabattoni G., Barnes P.J., et al. Increased exhaled 8-isoprostane in childhood asthma. Chest 124 (2003) 25-31
21. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., and Garg M.L. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 35 (2000) 967-974
22. 2α- isoprostane in cystic fibrosis. Lipids 34 (1999) 551-556
23. Vassalle C., Petrozzi L., Botto N., Andreassi M.G., and Zucchelli G.C. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Int Med 256 (2004) 308-315
24. Nanji A.A., Khwaja S., Tahan S.R., and Sadrzadeh S.M.H. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J Pharmacol Exp Ther 269 (1994) 1280-1285
25. Sanjiv J.K., Pemberton P.W., Smith A., McMahon R.F.T., Burrows P.C., Aboutwerat A., et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. Journal of Hepatology 36 (2002) 805-811
26. Pemberton P.W., Aboutwerat A., Smith A., Burrows P.C., McMahon R.F.T., and Warns T.W. Oxidant stress in type I autoimmune hepatitis: the link between necroinflammation and fibrogenesis?. Biochimica et Biophysica Acta 1689 (2004) 182-189
27. Basu S. Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity. Biochem Biophys Res Commun 254 (1999) 764-767
28. 2-isoprostane in bile: A novel index of hepatic lipid peroxidation. Hepatology 22 (1995) 962-968
29. 2-isoprostanes) in smokers. NEJM 332 (1995) 1198-1203
30. Oguogho A., Lupattelli G., Palumbo B., and Sinzinger H. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. Vasa 29 (2000) 103-105
31. Flores L., Vidal M., Abian J., Casest A., Ma J., Campistol J., et al. The effects of smoking and its cessation on 8-epi-PGF2α and transforming growth factor-beta 1 in type 1 diabetes mellitus. Diabetic Medicine 21 (2004) 285-289
32. 2t-isoprostane in rats. Free Radic Bio Med 34 (2003) 1435-1446
33. Owen J.A., Iggo B., Scandrett F.J., and Stewart C.P. The determination of creatinine in plasma or serum, and in urine; a critical examination. Biochem J 58 (1954) 426-437
34. 2t-isoprostane in rats. Free Radic Biol Med 38 (2005) 1471-1483
35. Hurd R.W., Van Rinsvelt H.A., Wilder B.J., Karas B., Maenhaut W., and De Reu L. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. Neurology 34 (1984) 1393-1395
36. Cengiz M., Yuksel A., and Seven M. The effects of carbamazepine and valproic acid on the erythrocyte glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children. Pharmacol Res 41 (2000) 423-425
37. Yuksel A., Cengiz M., Seven M., and Ulutin T. Erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children with valproate and carbamazepine therapy. J Basic Clin Physiol Pharmacol 11 (2000) 73-81
38. Tong V., Teng X.W., Chang T.K., and Abbott F.S. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci 86 (2005) 427-435
39. Hamed S.A., Abdellah M.M., and El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci 96 (2004) 465-473
40. Stewart R.J., Askew E.W., McDonald C.M., Metos J., Jackson W.D., Balon T.W., et al. Antioxidant status of young children: response to an antioxidant supplement. J Am Diet Assoc 102 (2002) 1652-1657
41. Schulpis K.H., Lazaropoulou C., Regoutas S., Karikas G.A., Margeli A., Tsakiris S., et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 217 (2006) 228-232
42. Sinzinger H., Oguogho A., and Pilz H. Increased isoprostanes in children of smoking parents. Adv Exp Med Biol 525 (2003) 213-215
43. Ahmadzadehfar H., Oguogho A., Efthimiou Y., Kritz H., and Sinzinger H. Passive cigarette smoking increases isoprostanes formation. Life Sciences 78 (2006) 894-897
44. National Health and Medical Research Council. The health effects of passive smoking. A scientific information paper (1997), NHMRC, Canberra
45. Church D.F., and Pryor W.A. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 64 (1985) 111-126